Are Analysts Bullish about Acorda Therapeutics, Inc. (NASDAQ:ACOR) after last week?

October 2, 2018 - By Hugh Holland

Acorda Therapeutics, Inc. (NASDAQ:ACOR) LogoInvestors sentiment increased to 1.45 in 2018 Q2. Its up 0.02, from 1.43 in 2018Q1. It improved, as 16 investors sold Acorda Therapeutics, Inc. shares while 46 reduced holdings. 34 funds opened positions while 56 raised stakes. 47.68 million shares or 1.76% less from 48.53 million shares in 2018Q1 were reported.
D E Shaw & reported 565,884 shares stake. Voya Mngmt Ltd reported 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Connecticut-based Aqr Mngmt Ltd Llc has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Parkside Comml Bank And Trust invested 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Shanda Asset Mgmt has invested 0.12% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Water Island Cap Limited Liability reported 100,000 shares stake. Tci Wealth Advisors reported 72 shares. Teachers Retirement System Of The State Of Kentucky stated it has 10,679 shares. Hbk Investments Limited Partnership holds 28,100 shares or 0.01% of its portfolio. Arrowstreet Partnership has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Profund Advsr Ltd Com has 0.01% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 8,512 shares. Proshare Advisors Lc reported 27,041 shares. State Street holds 1.86 million shares. New York-based Kazazian Asset Mgmt Ltd Co has invested 0.38% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Matarin Capital Mngmt Limited Liability owns 160,810 shares or 0% of their US portfolio.

Since May 2, 2018, it had 0 insider buys, and 21 selling transactions for $46.81 million activity. Shares for $172,471 were sold by Sabella Lauren M on Friday, May 18. On Friday, June 15 the insider SMITH IAN F sold $785,568. $245,853 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) was sold by RAUSCHER STEVEN M. SCOPIA CAPITAL MANAGEMENT LP also sold $6.86 million worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares. The insider LAWRENCE DAVID sold 25,000 shares worth $704,783. Another trade for 5,000 shares valued at $148,050 was sold by BLANK BURKHARD.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

Among 3 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Acorda Therapeutics had 6 analyst reports since May 2, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, May 30. The firm earned “Buy” rating on Thursday, May 3 by H.C. Wainwright. The firm has “Hold” rating given on Tuesday, August 7 by Stifel Nicolaus. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Hold” rating given on Wednesday, May 2 by Cantor Fitzgerald. The company was maintained on Monday, June 11 by H.C. Wainwright. Below is a list of Acorda Therapeutics, Inc. (NASDAQ:ACOR) latest ratings and price target changes.

23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $32 Initiates Coverage On
07/08/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $15 New Target: $25 Maintain
11/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $31.0000 Maintain
30/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $31.0000 Maintain
03/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $31.0000 Maintain
02/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0000 Maintain

The stock decreased 4.53% or $0.9 during the last trading session, reaching $18.88. About 374,672 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 20.26% since October 2, 2017 and is downtrending. It has underperformed by 35.88% the S&P500.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $896.26 million. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

More recent Acorda Therapeutics, Inc. (NASDAQ:ACOR) news were published by: Nasdaq.com which released: “Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today” on September 10, 2018. Also Seekingalpha.com published the news titled: “Acorda down 15% on adverse patent ruling” on September 10, 2018. Businesswire.com‘s news article titled: “Acorda to Present Data for INBRIJAâ„¢ (levodopa inhalation powder) at International Congress of Parkinson’s Disease …” with publication date: October 02, 2018 was also an interesting one.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>